Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Mira Kyivska
Mira Kyivska

AbbVie stock edges lower after European Commission approval for pJIA treatment

AbbVie stock edges lower after European Commission approval for pJIA treatment
AbbVie stock edges lower to $262.46

AbbVie said the European Commission has approved its treatment for active polyarticular juvenile idiopathic arthritis in children as young as two who have not responded to DMARDs. Shares edge lower on the day, trading at $262.46.

ABBV price prediction
24H 0.19%
$291.87
48H 0.5%
$292.77
7D 0.6%
$293.06
1M 6.06%
$308.96
3M 14.63%
$333.94
6M 7.47%
$313.07
12M 29.95%
$378.55
Detailed
Current price: $291.31 3.07 1.07%
Closed 11/06
Daily range 281.96 Arrow from to Icon 291.66
Weekly range 281.96 Arrow from to Icon 302.68
Loading...

Highlights

  • The European Commission approved AbbVie's RINVOQ oral solution for pediatric polyarticular juvenile idiopathic arthritis patients as young as two who do not respond to DMARDs.
  • Analyst coverage remains strongly positive with 98 of 124 rating AbbVie stock a buy and a median price target of $282.
  • Shares edge lower on the day, trading at $262.46.

AbbVie announced that the European Commission has approved its treatment for active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have not responded adequately to DMARDs. A new oral solution of RINVOQ was approved for use in pediatric pJIA patients, PR Newswire reported. The approval is based on efficacy and safety results from the SELECT-YOUTH Phase 1 study, according to BioPharmaWatch.

Stock holds bullish structure as overbought readings limit upside

AbbVie stock opened the session with a gap down from $264.53 to $261.58. Price remains above its MA-20, MA-50, and MA-200, keeping the daily structure bullish overall. The nearest support is the weekly low at $260.98, and with Stoch RSI in overbought territory, there is limited room for further upside.

High probability favors upside as traders watch $266.46 close

A close above $266.46 would indicate buyers are prepared to push price higher, while a drop below $260.98 would suggest the move is being faded. After opening lower at $261.58 from the previous close of $264.53, shares have partially recovered some ground. Over the next five trading days, the probability of an upside move is more than 80%, while the downside probability is less than 20%, with an expected trading range of $260 to $264.91. The recent move has been contained within a narrow range, but the longer-term weekly chart remains firmly constructive.

Previously it was reported that analysts viewed AbbVie’s ongoing partnerships and innovation pipeline as supporting a consolidation phase just below recent highs. The latest European Commission approval for pediatric arthritis treatment adds further clinical momentum to the bullish technical structure, with the key level to watch now at the recent gap-fill area near $264.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

From affair to market crash: How the Nvidia scandal hit Bitcoin
  • By Anastasiia Chabaniuk
  • 3 hours ago
From affair to market crash: How the Nvidia scandal hit Bitcoin
Editors' Picks
Shield AI’s Echodyne deal and the global counter-drone race
  • By Dmytro Kharkov
  • 4 hours ago
Shield AI’s Echodyne deal and the global counter-drone race
Editors' Picks
From airline tickets to Ferraris: What can you buy with crypto?
  • By Pavlo Kot
  • Yesterday
From airline tickets to Ferraris: What can you buy with crypto?
Editors' Picks
All Editors' Top Picks

Latest AbbVie News

AbbVie stock weekly forecast: MACD and ADX support further upside as momentum trends higher
  • By Yaroslav Dmytrenko
  • 03.11.2026
AbbVie stock weekly forecast: MACD and ADX support further upside as momentum trends higher
Stocks
#Forecast #AbbVie
AbbVie shares drop almost 2% after strong Q3 results and raised dividend
  • By Hlib Chabaniuk
  • 02.11.2026
AbbVie shares drop almost 2% after strong Q3 results and raised dividend
Stocks
#Forecast #AbbVie
AbbVie shares Q3 2026 financial results after stock ends session up 1.7%
  • By Yaroslav Dmytrenko
  • 30.10.2026
AbbVie shares Q3 2026 financial results after stock ends session up 1.7%
Companies
#AbbVie
All AbbVie News
  • Anastasiia Chabaniuk
  • 3 hours ago
From affair to market crash: How the Nvidia scandal hit Bitcoin
  • Dmytro Kharkov
  • 4 hours ago
Shield AI’s Echodyne deal and the global counter-drone race
  • Pavlo Kot
  • Yesterday
From airline tickets to Ferraris: What can you buy with crypto?
  • Pavlo Kot
  • 07.11.2026
Apartment or Bitcoin: Choosing a safe haven for your wealth
  • Dmytro Kharkov
  • 06.11.2026
CVS Health’s $117B split: Defensive spin-off or end of healthcare vertical integration?
  • Oksana Koneva
  • 7 min ago
Gordon Johnson: Nvidia CEO admits affair as board investigates spy claims
  • Pavlo Kot
  • 12 min ago
Investors weigh likelihood Jensen Huang remains CEO, Dan Ives notes
  • Elena Nikulina
  • 13 min ago
Andy Constan: Purr has fallen 30 percent and HYPE 25 percent in under two weeks
  • Mikhail Vnuchkov
  • 13 min ago
James Stanley: Market awaits CPI data and cloud company earnings for rate and corporate context
  • Yulia Slavina
  • 26 min ago
Kate Miller: Giveaway of three Drip Habibis NFTs on Solana includes rare and gold editions
Top News
  • Oleg Tkachenko
  • 1 hour ago
U.S. authorities grant Coinbase a banking charter
U.S. authorities grant Coinbase a banking charter
  • Olga Shendetskaya
  • 2 hours ago
Oil prices fall after Trump's comments on Iran
Oil prices fall after Trump's comments on Iran
  • Pavlo Kot
  • 4 hours ago
Binance, Tether and Trump-linked crypto firms face congressional scrutiny
Binance, Tether and Trump-linked crypto firms face congressional scrutiny
  • Dmytro Kharkov
  • 4 hours ago
Shield AI’s Echodyne deal and the global counter-drone race
Shield AI’s Echodyne deal and the global counter-drone race
  • Eugene Komchuk
  • 5 hours ago
Nvidia shares tumble amid espionage scandal involving CEO
Nvidia shares tumble amid espionage scandal involving CEO
Live News
  • Mykhailo Ihnatenko
  • Now
Nvidia stock falls amid CEO scrutiny: Can buyers reclaim $178?
  • Anton Kharitonov
  • Now
EUR/USD targets 1.1200 as dollar weakens ahead of U.S. inflation data
  • Mykhailo Ihnatenko
  • Now
Ethereum slides as geopolitical risks trigger another $1B liquidation wave
  • Pavlo Kot
  • Now
Binance hackers still hold $3.1 billion in cryptocurrency after attack
  • Mykhailo Ihnatenko
  • Now
AMD stock attempts recovery after sharp sell-off wipes out post-earnings gains
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers